Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested
Reviewed 18 sourcesPublished by PepVault
No label converts one GLP-1 to another. What the labels say on each switch, Ozempic to Zepbound, shot to pill, CagriSema, and what the switch trials found.

- Last reviewed
- Sources
- 18
- Questions
- 7
- Compounds
- 6
The short answer
No label gives a conversion from one GLP-1 to another. The only switch rules on a label stay inside semaglutide: one week after the last Wegovy 2.4 mg shot, the Wegovy pill starts at 25 mg. For Ozempic to Zepbound, the Zepbound label starts everyone at 2.5 mg. Trials have tested a few switches; the prescriber sets the rest.
Evidence: Label rules for switches within semaglutide; two open-label switch studies into tirzepatide in type 2 diabetes (12 weeks single-arm, and 40 weeks randomized from dulaglutide); one randomized trial of moving from a shot to orforglipron; no trials yet for CagriSema or retatrutide.

Is there a conversion chart for switching GLP-1s?
Not from the makers. The Zepbound, Wegovy and Foundayo labels each say their drug is not to be used together with another GLP-1 medicine, and none of them tells a prescriber how to move someone over from a different drug124. The only conversions printed on a label stay inside one molecule, semaglutide: the Wegovy shot to the Wegovy pill and back2, and Ozempic 0.5 mg to Rybelsus or Ozempic tablets3.
The "Ozempic to Zepbound conversion charts" that rank in search are put together by websites, not by Novo Nordisk or Eli Lilly. An expert review published in November 2026 opens with the same point: there are no guidelines for switching from semaglutide to tirzepatide. Its authors propose approximate dose bands for prescribers to use until switching trials confirm exact conversions11.
Switching in PepVault: finish the old protocol and start a new one. Finishing archives it with today's end date, and every dose, weight and side effect you logged stays. Log it in PepVault

Which GLP-1 switches have been tested, and what do the labels say?
One row per switch people ask about. "Label" is the US prescribing information as of November 2026; "trials" is what has been tested or registered.
| Switch | What the label says | What trials tested | Our deeper guide |
|---|---|---|---|
| Ozempic or Wegovy to Zepbound or Mounjaro (semaglutide to tirzepatide) | No switch rule. Zepbound starts at 2.5 mg weekly for 4 weeks, then steps up by 2.5 mg1 | SURPASS-SWITCH-2: type 2 diabetes, from any of three GLP-1s (55% on semaglutide), straight to 5 mg for 12 weeks5. No reported trial in people without diabetes | Semaglutide vs tirzepatide side effects; Ozempic, Wegovy, Mounjaro and Zepbound |
| Zepbound to Wegovy or Ozempic (tirzepatide to semaglutide) | No switch rule. The Wegovy shot starts at 0.25 mg weekly for 4 weeks2 | None found in the registry or PubMed | Ozempic, Wegovy, Mounjaro and Zepbound |
| Wegovy shot to Wegovy pill | One week after the last 2.4 mg shot, start 25 mg tablets once daily2 | The label's own rule | The Wegovy pill |
| Wegovy pill to Wegovy shot | The day after the last 25 mg tablet, start 2.4 mg weekly; 1.7 mg if 25 mg tablets were not tolerated2 | The label's own rule | The Wegovy pill |
| Ozempic shot to Rybelsus or Ozempic tablets | From Ozempic 0.5 mg only: one week later, Rybelsus 7 or 14 mg, or Ozempic tablets 4 or 9 mg3 | The label's own rule | The Wegovy pill |
| Zepbound or Wegovy to Foundayo (orforglipron) | No switch rule. Foundayo starts at 0.8 mg daily for at least 30 days4 | ATTAIN-MAINTAIN: straight to the 9 mg tablet dose within 14 days of the last shot7 | Foundayo vs the shots; Keeping weight off after a GLP-1 |
| Ozempic or Wegovy to CagriSema | Not FDA approved | A phase 3 switch trial is recruiting: type 2 diabetes, three switch regimens8 | CagriSema vs Zepbound vs Wegovy |
| Zepbound to retatrutide | Not FDA approved | None. TRIUMPH-1, the main phase 3 obesity trial, excluded anyone who took a weight-loss drug in the 90 days before screening9 | Switching from tirzepatide to retatrutide |
| A GLP-1 shot to aleniglipron (a pill in trials) | Not FDA approved | Structure Therapeutics' SWITCH study: from an approved GLP-1 shot, several starting doses, 12 weeks; results expected Q4 2026, per the company17 | Aleniglipron and its switch trial |
| Compounded semaglutide or tirzepatide to a brand | No switch rule; FDA does not review compounded drugs for safety, effectiveness or quality10 | None. The CagriSema switch trial excludes people on compounded semaglutide8 | Is compounded semaglutide the same as Ozempic? |
What happened when people switched from semaglutide to tirzepatide?
The one prospective test of moving straight onto tirzepatide is SURPASS-SWITCH-2, a Lilly-run study of 152 adults with type 2 diabetes on a stable dose of liraglutide, semaglutide or dulaglutide for at least three months: 55% were on semaglutide (most often 1.0 mg) and 42% on dulaglutide. Everyone moved straight to tirzepatide 5 mg, skipping the 2.5 mg starting step, and stayed there for 12 weeks5.
Over those 12 weeks HbA1c (the three-month blood sugar average) fell by a further 0.43 points and weight by a further 2.15 kg, on top of what the earlier drug had done. Stomach side effects showed up in 20 people (13.2%), and 3 (2%) stopped tirzepatide because of side effects5. The study had no comparison group. Our reading: 5 mg is the lowest maintenance dose on the Zepbound label, so these numbers describe the first 12 weeks, not where tirzepatide tops out1.
The longer trial switched from dulaglutide, not semaglutide. In SURPASS-SWITCH, 282 adults on low-dose dulaglutide either moved to tirzepatide, starting at 2.5 mg and stepping up to 15 mg or the highest dose they tolerated, or stepped dulaglutide up. At 40 weeks weight was down 10.5 kg on tirzepatide against 3.6 kg on more dulaglutide6. Beyond these, there is a chart review of 15 people with type 2 diabetes in Japan who moved from semaglutide 1.0 mg to tirzepatide starting at 2.5 mg12, and a Canadian registry study of about 650 people (switchers with and without diabetes, plus a group that stayed on semaglutide), with primary completion estimated for December 2026 on ClinicalTrials.gov13. No trial has yet tested this switch in people without diabetes.
What happened when people moved from a GLP-1 shot to Foundayo?
ATTAIN-MAINTAIN took 376 people who had just finished 72 weeks of Zepbound or Wegovy in SURMOUNT-5 and gave them orforglipron (Foundayo) or a placebo pill. The first pill came, ideally, within 14 days of the last shot, and it started at the dose equal to the 9 mg tablet, not the 0.8 mg the label sets for new users. It then stepped up every 4 weeks to the 17.2 mg tablet dose or the highest dose each person tolerated7.
The jump went smoothly: in the first 4 weeks, 10.5% of those coming off Zepbound and 9.5% of those coming off Wegovy had nausea, vomiting or diarrhea, mostly mild to moderate, and nobody needed a lower dose7. Among people whose weight had levelled off on the shot, the pill kept 74.7% (from Zepbound) and 79.3% (from Wegovy) of the loss after a year, against 49.2% and 37.6% on placebo; Keeping weight off after a GLP-1 takes that result further. The trial had no group that stayed on the shot7.
The 9 mg start is the trial's, not the label's. As of its August 2026 version, the Foundayo label still starts at 0.8 mg and gives no rule for coming off a shot4.
How long does the old GLP-1 stay in your body after a switch?
Weeks, which is why the gap between drugs matters. A half-life is the time it takes for half of a drug to leave the body. Semaglutide's is about one week, and the Wegovy label says it stays in the blood for about 5 to 7 weeks after the last 2.4 mg shot or 25 mg tablet2. Tirzepatide's is about 5 days1. The chart shows how a weekly semaglutide dose fades after the last shot.
Try it
How Semaglutide builds up
An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.
The labels' own gaps are short: one week from the Wegovy shot to the pill, and the next day from the pill to the shot2. So the first dose of the new form lands while semaglutide from the old one is still in the blood.
Which GLP-1 switch trials are coming?
These switch trials are registered and not yet reported, as of November 20, 2026; every date is the registry's estimate.
| Trial | Switch | People | Primary completion (ClinicalTrials.gov) |
|---|---|---|---|
| NCT07817251 (Novo Nordisk, phase 3) | Semaglutide 1.0 or 2.0 mg to CagriSema, three regimens; side effects to week 168 | 210, type 2 diabetes | June 9, 2027 |
| MARITIME-SWITCH, NCT07575399 (Amgen, phase 3) | A weekly GLP-1 to MariTide, two schedules; weight at week 6814 | 300 without diabetes, at least 10% lost on the weekly drug | January 3, 2028 |
| VESPER-SWITCH, NCT07845500 (Pfizer, phase 3) | Weekly semaglutide or tirzepatide to monthly berobenatide, against staying on; weight at week 3215 | 660 without diabetes | February 16, 2028 |
| SYNCHRONIZE-START, NCT07855900 (Boehringer Ingelheim, phase 3b) | Semaglutide or tirzepatide to survodutide, beside people starting fresh; weight at week 5218 | 350 without diabetes | November 6, 2029 |
| NCT07868354 (Novo Nordisk, phase 1) | Tirzepatide maintenance dose to zenagamtide; side effects to day 5716 | 60, with or without type 2 diabetes | September 7, 2028 |
In the CagriSema trial, people on Ozempic or Wegovy move to CagriSema at one of three doses; two arms then step down to a lower dose, and the record counts side effects over 16 weeks8.
What should you settle with your prescriber before switching GLP-1s?
- Write down your current drug, dose, and the date and time of your last dose. Every timing question starts from that date.
- Ask which day the first dose of the new drug falls on. Where a label sets it, it is one week after the last Wegovy shot for the pill, and the next day from the pill to the shot2.
- Ask what the starting dose is and why. Zepbound's label starts at 2.5 mg and Foundayo's at 0.8 mg14; a higher start, as in SURPASS-SWITCH-2 or ATTAIN-MAINTAIN, is the trial's, and your prescriber decides if it applies57.
- Ask how the steps up go: at least 4 weeks per step on Zepbound, at least 30 days on Foundayo14.
- Ask about the overlap. The labels advise against taking two GLP-1 medicines together, so the old drug stops before the new one starts124.
- If you take the pill for birth control, ask about backup. The Zepbound label advises a non-oral or barrier method for 4 weeks after starting and after each step up, and Foundayo's for 30 days14.
- Log your weight and any side effects from the first new dose, so the next visit runs on your own numbers.
Commonly reported: in the switch trials, nausea, constipation, diarrhea or vomiting in the first weeks on the new drug, mostly mild to moderate57.
PepVault keeps your weigh-ins on one chart across both protocols, so the weeks before and after the switch sit side by side. Track your weight in PepVault
When to get help Severe stomach pain that does not ease, sometimes reaching the back, is a reason to stop the drug and contact your prescriber promptly, as the labels advise14.
Sources
- ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, SPL version 40, revised 08/2026. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablets, prescribing information. Novo Nordisk. DailyMed, SPL version 19, revised 06/2026. dailymed.nlm.nih.gov
- RYBELSUS and OZEMPIC (semaglutide) tablets, prescribing information. Novo Nordisk. DailyMed, SPL version 14, revised 01/2026. dailymed.nlm.nih.gov
- FOUNDAYO (orforglipron) tablets, prescribing information. Eli Lilly and Company. DailyMed, SPL version 10, 2026. dailymed.nlm.nih.gov
- Jabbour S et al. Switching to tirzepatide 5 mg from glucagon-like peptide-1 receptor agonists: clinical expectations in the first 12 weeks of treatment (SURPASS-SWITCH-2). Endocr Pract. 2024. PubMed 38723893
- Billings LK et al. Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide (SURPASS-SWITCH). Ann Intern Med. 2025. PubMed 40183678
- Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PubMed 42120723
- Safety and tolerability of 3 switch regimens from semaglutide 1.0 mg and 2.0 mg to CagriSema in participants with type 2 diabetes. Novo Nordisk. ClinicalTrials.gov NCT07817251. clinicaltrials.gov
- TRIUMPH-1: retatrutide in participants who have obesity or overweight. Eli Lilly and Company. ClinicalTrials.gov NCT05929066 (eligibility criteria). clinicaltrials.gov
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration. Content current as of October 1, 2026. fda.gov
- Schwartzberg E et al. Switching between semaglutide and tirzepatide in obesity management: an expert-consensus framework for approximate clinical efficacy-matched switching doses. Expert Opin Pharmacother. 2026. PubMed 42952336
- Kurinami N et al. Early dose escalation of tirzepatide after switching from semaglutide in type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2025. PubMed 41088952
- Metabolic effects of switching from injectable semaglutide to tirzepatide: a retrospective study of the LMC Diabetes Registry. ClinicalTrials.gov NCT07889453. clinicaltrials.gov
- Switching from GLP-1 receptor agonists to maridebart cafraglutide in adults with obesity or overweight. Amgen. ClinicalTrials.gov NCT07575399. clinicaltrials.gov
- VESPER-SWITCH: the switch to monthly berobenatide for maintaining weight in adults on weekly semaglutide or tirzepatide. Pfizer. ClinicalTrials.gov NCT07845500. clinicaltrials.gov
- Tolerability when switching from tirzepatide to zenagamtide in participants with overweight or obesity. Novo Nordisk. ClinicalTrials.gov NCT07868354. clinicaltrials.gov
- Structure Therapeutics. Third quarter 2026 financial results and recent highlights (Form 8-K, Exhibit 99.1). November 9, 2026. sec.gov
- SYNCHRONIZE-START: initiation strategies for survodutide, including switching from semaglutide or tirzepatide, in people with overweight or obesity without diabetes. Boehringer Ingelheim. ClinicalTrials.gov NCT07855900. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.